Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186


A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.

Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, van der Walt NT, Türler A, Schibli R.

J Nucl Med. 2012 Dec;53(12):1951-9. doi: 10.2967/jnumed.112.107540. Epub 2012 Nov 8.


DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.

Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R.

J Nucl Med. 2013 Jan;54(1):124-31. doi: 10.2967/jnumed.112.107235. Epub 2012 Dec 12.


Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate.

Müller C, Bunka M, Reber J, Fischer C, Zhernosekov K, Türler A, Schibli R.

J Nucl Med. 2013 Dec;54(12):2168-74. doi: 10.2967/jnumed.113.123810. Epub 2013 Nov 6.


Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.

Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, Türler A, Schibli R.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):476-85. doi: 10.1007/s00259-013-2563-z. Epub 2013 Oct 8.


[149/152/155/161Tb]-Labeled DOTA-folate conjugated to an albumin-binding entity.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Dec 3 [updated 2012 Dec 27].


Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice.

Müller C, Fischer E, Behe M, Köster U, Dorrer H, Reber J, Haller S, Cohrs S, Blanc A, Grünberg J, Bunka M, Zhernosekov K, van der Meulen N, Johnston K, Türler A, Schibli R.

Nucl Med Biol. 2014 May;41 Suppl:e58-65. doi: 10.1016/j.nucmedbio.2013.11.002. Epub 2013 Nov 15.


Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice.

Müller C, Bunka M, Haller S, Köster U, Groehn V, Bernhardt P, van der Meulen N, Türler A, Schibli R.

J Nucl Med. 2014 Oct;55(10):1658-64. doi: 10.2967/jnumed.114.141614. Epub 2014 Jul 17.


Synthesis and Preclinical Evaluation of Folate-NOTA-Al(18)F for PET Imaging of Folate-Receptor-Positive Tumors.

Chen Q, Meng X, McQuade P, Rubins D, Lin SA, Zeng Z, Haley H, Miller P, González Trotter D, Low PS.

Mol Pharm. 2016 May 2;13(5):1520-7. doi: 10.1021/acs.molpharmaceut.5b00989. Epub 2016 Apr 18.


In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.

Fani M, Tamma ML, Nicolas GP, Lasri E, Medina C, Raynal I, Port M, Weber WA, Maecke HR.

Mol Pharm. 2012 May 7;9(5):1136-45. doi: 10.1021/mp200418f. Epub 2012 Apr 23.


Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.

Kim WH, Kim CG, Kim MH, Kim DW, Park CR, Park JY, Lee YS, Youn H, Kang KW, Jeong JM, Chung JK.

Ann Nucl Med. 2016 Jun;30(5):369-79. doi: 10.1007/s12149-016-1072-0. Epub 2016 Mar 18.


Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging.

Müller C, Vermeulen C, Johnston K, Köster U, Schmid R, Türler A, van der Meulen NP.

EJNMMI Res. 2016 Dec;6(1):35. doi: 10.1186/s13550-016-0189-4. Epub 2016 Apr 23.


Folate receptor targeted alpha-therapy using terbium-149.

Müller C, Reber J, Haller S, Dorrer H, Köster U, Johnston K, Zhernosekov K, Türler A, Schibli R.

Pharmaceuticals (Basel). 2014 Mar 13;7(3):353-65. doi: 10.3390/ph7030353.


SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate.

Müller C, Forrer F, Schibli R, Krenning EP, de Jong M.

J Nucl Med. 2008 Feb;49(2):310-7. doi: 10.2967/jnumed.107.045856. Epub 2008 Jan 16.


(64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.

Farkas R, Siwowska K, Ametamey SM, Schibli R, van der Meulen NP, Müller C.

Mol Pharm. 2016 Jun 6;13(6):1979-87. doi: 10.1021/acs.molpharmaceut.6b00143. Epub 2016 May 4.


Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy.

Müller C, Mindt TL, de Jong M, Schibli R.

Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):938-46. doi: 10.1007/s00259-008-1058-9. Epub 2009 Jan 30.


Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.

Ross TL, Honer M, Lam PY, Mindt TL, Groehn V, Schibli R, Schubiger PA, Ametamey SM.

Bioconjug Chem. 2008 Dec;19(12):2462-70. doi: 10.1021/bc800356r.


Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates.

Fani M, Wang X, Nicolas G, Medina C, Raynal I, Port M, Maecke HR.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):108-19. doi: 10.1007/s00259-010-1597-8. Epub 2010 Aug 27.


Tumor targeting using 67Ga-DOTA-Bz-folate--investigations of methods to improve the tissue distribution of radiofolates.

Müller C, Vlahov IR, Santhapuram HK, Leamon CP, Schibli R.

Nucl Med Biol. 2011 Jul;38(5):715-23. doi: 10.1016/j.nucmedbio.2010.12.013. Epub 2011 Mar 3.


Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Grünberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhernosekov K, Köster U, Türler A, Fischer E, Schibli R.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1907-15. doi: 10.1007/s00259-014-2798-3. Epub 2014 May 24.


Comparative Studies of Three Pairs of α- and γ-Conjugated Folic Acid Derivatives Labeled with Fluorine-18.

Boss SD, Betzel T, Müller C, Fischer CR, Haller S, Reber J, Groehn V, Schibli R, Ametamey SM.

Bioconjug Chem. 2016 Jan 20;27(1):74-86. doi: 10.1021/acs.bioconjchem.5b00644. Epub 2015 Dec 11.


Supplemental Content

Support Center